What is the current valuation of the Radioligand Therapy (RLT) Market as of 2024?

The Radioligand Therapy (RLT) Market was valued at 8.14 USD Billion in 2024. Read More

What is the projected market size for the Radioligand Therapy (RLT) Market by 2035?

The market is projected to reach 21.89 USD Billion by 2035. Read More

What is the expected CAGR for the Radioligand Therapy (RLT) Market during the forecast period 2025 - 2035?

The expected CAGR for the Radioligand Therapy (RLT) Market during 2025 - 2035 is 9.41%. Read More

Which companies are considered key players in the Radioligand Therapy (RLT) Market?

Key players in the market include Novartis, Bayer, Bristol-Myers Squibb, AstraZeneca, Elekta, Siemens Healthineers, GE Healthcare, and Lantheus Medical Imaging. Read More

What are the projected revenues for the Lutetium-177 segment by 2035?

The Lutetium-177 segment is projected to generate revenues of 8.0 USD Billion by 2035. Read More

How does the Prostate-specific Membrane Antigen (PSMA) segment perform in terms of revenue?

The PSMA segment is expected to grow from 2.5 USD Billion in 2024 to 6.5 USD Billion by 2035. Read More

What is the revenue forecast for hospitals and clinics as end users in the RLT Market?

Revenues from hospitals and clinics as end users are projected to increase from 3.24 USD Billion in 2024 to 8.67 USD Billion by 2035. Read More

What is the expected growth for the Neuroendocrine Tumors (NETs) segment by 2035?

The Neuroendocrine Tumors (NETs) segment is anticipated to grow from 2.0 USD Billion in 2024 to 5.5 USD Billion by 2035. Read More

What is the revenue outlook for the Gallium-68 segment in the RLT Market?

The Gallium-68 segment is projected to grow from 2.0 USD Billion in 2024 to 5.5 USD Billion by 2035. Read More

How does the RLT Market's growth compare across different end-user segments?

The RLT Market shows varied growth across end-user segments, with diagnostic centers expected to grow from 2.45 USD Billion in 2024 to 6.45 USD Billion by 2035. Read More

Radioligand Therapy RLT Market

ID: MRFR/Pharma/10303-HCR

128 Pages

Rahul Gotadki

Last Updated: May 15, 2026

Radioligand Therapy (RLT) Market Size, Growth Research Report By Isotope (Fluorine – 18, Gallium – 68, Lutetium – 177, and Others), By Targeted Receptor (Prostate-specific Membrane Antigen (PSMA), Somatostatin Receptor (SSTR), Epidermal Growth Factor Receptor (EGFR), and Others), By Indication (Prostate Cancer, Neuroendocrine Tumors (NETs), Breast Cancer, and Others), By End User (Hospitals & Clinics, Diagnostic Centers, and Others), and By Region (North America, Europe, Asia-Pacific, and Rest of the World) - Competitor Industry Analysis and Trends Forecast Till 2035

Radioligand Therapy RLT Market Infographic

Summary Table of Contents Segmentation Methodology Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Isotope (USD Billion)
  1. 4.1.1 Fluorine - 18
  2. 4.1.2 Gallium - 68
  3. 4.1.3 Lutetium - 177
  4. 4.1.4 Others
2. 4.2 Healthcare, BY Targeted Receptor (USD Billion)
  1. 4.2.1 Prostate-specific Membrane Antigen (PSMA)
  2. 4.2.2 Somatostatin Receptor (SSTR)
  3. 4.2.3 Epidermal Growth Factor Receptor (EGFR)
  4. 4.2.4 Others
3. 4.3 Healthcare, BY Indication (USD Billion)
  1. 4.3.1 Prostate Cancer
  2. 4.3.2 Neuroendocrine Tumors (NETs)
  3. 4.3.3 Breast Cancer
  4. 4.3.4 Others
4. 4.4 Healthcare, BY End User (USD Billion)
  1. 4.4.1 Hospitals & Clinics
  2. 4.4.2 Diagnostic Centers
  3. 4.4.3 Others
5. 4.5 Healthcare, BY Region (USD Billion)
  1. 4.5.1 North America
    1. 4.5.1.1 US
    2. 4.5.1.2 Canada
  2. 4.5.2 Europe
    1. 4.5.2.1 Germany
    2. 4.5.2.2 UK
    3. 4.5.2.3 France
    4. 4.5.2.4 Russia
    5. 4.5.2.5 Italy
    6. 4.5.2.6 Spain
    7. 4.5.2.7 Rest of Europe
  3. 4.5.3 APAC
    1. 4.5.3.1 China
    2. 4.5.3.2 India
    3. 4.5.3.3 Japan
    4. 4.5.3.4 South Korea
    5. 4.5.3.5 Malaysia
    6. 4.5.3.6 Thailand
    7. 4.5.3.7 Indonesia
    8. 4.5.3.8 Rest of APAC
  4. 4.5.4 South America
    1. 4.5.4.1 Brazil
    2. 4.5.4.2 Mexico
    3. 4.5.4.3 Argentina
    4. 4.5.4.4 Rest of South America
  5. 4.5.5 MEA
    1. 4.5.5.1 GCC Countries
    2. 4.5.5.2 South Africa
    3. 4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Novartis (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bayer (DE)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Bristol-Myers Squibb (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 AstraZeneca (GB)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Elekta (SE)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Siemens Healthineers (DE)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 GE Healthcare (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Lantheus Medical Imaging (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY ISOTOPE
4. 6.4 US MARKET ANALYSIS BY TARGETED RECEPTOR
5. 6.5 US MARKET ANALYSIS BY INDICATION
6. 6.6 US MARKET ANALYSIS BY END USER
7. 6.7 CANADA MARKET ANALYSIS BY ISOTOPE
8. 6.8 CANADA MARKET ANALYSIS BY TARGETED RECEPTOR
9. 6.9 CANADA MARKET ANALYSIS BY INDICATION
10. 6.10 CANADA MARKET ANALYSIS BY END USER
11. 6.11 EUROPE MARKET ANALYSIS
12. 6.12 GERMANY MARKET ANALYSIS BY ISOTOPE
13. 6.13 GERMANY MARKET ANALYSIS BY TARGETED RECEPTOR
14. 6.14 GERMANY MARKET ANALYSIS BY INDICATION
15. 6.15 GERMANY MARKET ANALYSIS BY END USER
16. 6.16 UK MARKET ANALYSIS BY ISOTOPE
17. 6.17 UK MARKET ANALYSIS BY TARGETED RECEPTOR
18. 6.18 UK MARKET ANALYSIS BY INDICATION
19. 6.19 UK MARKET ANALYSIS BY END USER
20. 6.20 FRANCE MARKET ANALYSIS BY ISOTOPE
21. 6.21 FRANCE MARKET ANALYSIS BY TARGETED RECEPTOR
22. 6.22 FRANCE MARKET ANALYSIS BY INDICATION
23. 6.23 FRANCE MARKET ANALYSIS BY END USER
24. 6.24 RUSSIA MARKET ANALYSIS BY ISOTOPE
25. 6.25 RUSSIA MARKET ANALYSIS BY TARGETED RECEPTOR
26. 6.26 RUSSIA MARKET ANALYSIS BY INDICATION
27. 6.27 RUSSIA MARKET ANALYSIS BY END USER
28. 6.28 ITALY MARKET ANALYSIS BY ISOTOPE
29. 6.29 ITALY MARKET ANALYSIS BY TARGETED RECEPTOR
30. 6.30 ITALY MARKET ANALYSIS BY INDICATION
31. 6.31 ITALY MARKET ANALYSIS BY END USER
32. 6.32 SPAIN MARKET ANALYSIS BY ISOTOPE
33. 6.33 SPAIN MARKET ANALYSIS BY TARGETED RECEPTOR
34. 6.34 SPAIN MARKET ANALYSIS BY INDICATION
35. 6.35 SPAIN MARKET ANALYSIS BY END USER
36. 6.36 REST OF EUROPE MARKET ANALYSIS BY ISOTOPE
37. 6.37 REST OF EUROPE MARKET ANALYSIS BY TARGETED RECEPTOR
38. 6.38 REST OF EUROPE MARKET ANALYSIS BY INDICATION
39. 6.39 REST OF EUROPE MARKET ANALYSIS BY END USER
40. 6.40 APAC MARKET ANALYSIS
41. 6.41 CHINA MARKET ANALYSIS BY ISOTOPE
42. 6.42 CHINA MARKET ANALYSIS BY TARGETED RECEPTOR
43. 6.43 CHINA MARKET ANALYSIS BY INDICATION
44. 6.44 CHINA MARKET ANALYSIS BY END USER
45. 6.45 INDIA MARKET ANALYSIS BY ISOTOPE
46. 6.46 INDIA MARKET ANALYSIS BY TARGETED RECEPTOR
47. 6.47 INDIA MARKET ANALYSIS BY INDICATION
48. 6.48 INDIA MARKET ANALYSIS BY END USER
49. 6.49 JAPAN MARKET ANALYSIS BY ISOTOPE
50. 6.50 JAPAN MARKET ANALYSIS BY TARGETED RECEPTOR
51. 6.51 JAPAN MARKET ANALYSIS BY INDICATION
52. 6.52 JAPAN MARKET ANALYSIS BY END USER
53. 6.53 SOUTH KOREA MARKET ANALYSIS BY ISOTOPE
54. 6.54 SOUTH KOREA MARKET ANALYSIS BY TARGETED RECEPTOR
55. 6.55 SOUTH KOREA MARKET ANALYSIS BY INDICATION
56. 6.56 SOUTH KOREA MARKET ANALYSIS BY END USER
57. 6.57 MALAYSIA MARKET ANALYSIS BY ISOTOPE
58. 6.58 MALAYSIA MARKET ANALYSIS BY TARGETED RECEPTOR
59. 6.59 MALAYSIA MARKET ANALYSIS BY INDICATION
60. 6.60 MALAYSIA MARKET ANALYSIS BY END USER
61. 6.61 THAILAND MARKET ANALYSIS BY ISOTOPE
62. 6.62 THAILAND MARKET ANALYSIS BY TARGETED RECEPTOR
63. 6.63 THAILAND MARKET ANALYSIS BY INDICATION
64. 6.64 THAILAND MARKET ANALYSIS BY END USER
65. 6.65 INDONESIA MARKET ANALYSIS BY ISOTOPE
66. 6.66 INDONESIA MARKET ANALYSIS BY TARGETED RECEPTOR
67. 6.67 INDONESIA MARKET ANALYSIS BY INDICATION
68. 6.68 INDONESIA MARKET ANALYSIS BY END USER
69. 6.69 REST OF APAC MARKET ANALYSIS BY ISOTOPE
70. 6.70 REST OF APAC MARKET ANALYSIS BY TARGETED RECEPTOR
71. 6.71 REST OF APAC MARKET ANALYSIS BY INDICATION
72. 6.72 REST OF APAC MARKET ANALYSIS BY END USER
73. 6.73 SOUTH AMERICA MARKET ANALYSIS
74. 6.74 BRAZIL MARKET ANALYSIS BY ISOTOPE
75. 6.75 BRAZIL MARKET ANALYSIS BY TARGETED RECEPTOR
76. 6.76 BRAZIL MARKET ANALYSIS BY INDICATION
77. 6.77 BRAZIL MARKET ANALYSIS BY END USER
78. 6.78 MEXICO MARKET ANALYSIS BY ISOTOPE
79. 6.79 MEXICO MARKET ANALYSIS BY TARGETED RECEPTOR
80. 6.80 MEXICO MARKET ANALYSIS BY INDICATION
81. 6.81 MEXICO MARKET ANALYSIS BY END USER
82. 6.82 ARGENTINA MARKET ANALYSIS BY ISOTOPE
83. 6.83 ARGENTINA MARKET ANALYSIS BY TARGETED RECEPTOR
84. 6.84 ARGENTINA MARKET ANALYSIS BY INDICATION
85. 6.85 ARGENTINA MARKET ANALYSIS BY END USER
86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY ISOTOPE
87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY TARGETED RECEPTOR
88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY INDICATION
89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER
90. 6.90 MEA MARKET ANALYSIS
91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY ISOTOPE
92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY TARGETED RECEPTOR
93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY INDICATION
94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY END USER
95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY ISOTOPE
96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY TARGETED RECEPTOR
97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY INDICATION
98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY END USER
99. 6.99 REST OF MEA MARKET ANALYSIS BY ISOTOPE
100. 6.100 REST OF MEA MARKET ANALYSIS BY TARGETED RECEPTOR
101. 6.101 REST OF MEA MARKET ANALYSIS BY INDICATION
102. 6.102 REST OF MEA MARKET ANALYSIS BY END USER
103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
104. 6.104 RESEARCH PROCESS OF MRFR
105. 6.105 DRO ANALYSIS OF HEALTHCARE
106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
109. 6.109 HEALTHCARE, BY ISOTOPE, 2024 (% SHARE)
110. 6.110 HEALTHCARE, BY ISOTOPE, 2024 TO 2035 (USD Billion)
111. 6.111 HEALTHCARE, BY TARGETED RECEPTOR, 2024 (% SHARE)
112. 6.112 HEALTHCARE, BY TARGETED RECEPTOR, 2024 TO 2035 (USD Billion)
113. 6.113 HEALTHCARE, BY INDICATION, 2024 (% SHARE)
114. 6.114 HEALTHCARE, BY INDICATION, 2024 TO 2035 (USD Billion)
115. 6.115 HEALTHCARE, BY END USER, 2024 (% SHARE)
116. 6.116 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY ISOTOPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY TARGETED RECEPTOR, 2025-2035 (USD Billion)
  3. 7.2.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.2.4 BY END USER, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY ISOTOPE, 2025-2035 (USD Billion)
  2. 7.3.2 BY TARGETED RECEPTOR, 2025-2035 (USD Billion)
  3. 7.3.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.3.4 BY END USER, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY ISOTOPE, 2025-2035 (USD Billion)
  2. 7.4.2 BY TARGETED RECEPTOR, 2025-2035 (USD Billion)
  3. 7.4.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.4.4 BY END USER, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY ISOTOPE, 2025-2035 (USD Billion)
  2. 7.5.2 BY TARGETED RECEPTOR, 2025-2035 (USD Billion)
  3. 7.5.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.5.4 BY END USER, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY ISOTOPE, 2025-2035 (USD Billion)
  2. 7.6.2 BY TARGETED RECEPTOR, 2025-2035 (USD Billion)
  3. 7.6.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.6.4 BY END USER, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY ISOTOPE, 2025-2035 (USD Billion)
  2. 7.7.2 BY TARGETED RECEPTOR, 2025-2035 (USD Billion)
  3. 7.7.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.7.4 BY END USER, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY ISOTOPE, 2025-2035 (USD Billion)
  2. 7.8.2 BY TARGETED RECEPTOR, 2025-2035 (USD Billion)
  3. 7.8.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.8.4 BY END USER, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY ISOTOPE, 2025-2035 (USD Billion)
  2. 7.9.2 BY TARGETED RECEPTOR, 2025-2035 (USD Billion)
  3. 7.9.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.9.4 BY END USER, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY ISOTOPE, 2025-2035 (USD Billion)
  2. 7.10.2 BY TARGETED RECEPTOR, 2025-2035 (USD Billion)
  3. 7.10.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.10.4 BY END USER, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY ISOTOPE, 2025-2035 (USD Billion)
  2. 7.11.2 BY TARGETED RECEPTOR, 2025-2035 (USD Billion)
  3. 7.11.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.11.4 BY END USER, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY ISOTOPE, 2025-2035 (USD Billion)
  2. 7.12.2 BY TARGETED RECEPTOR, 2025-2035 (USD Billion)
  3. 7.12.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.12.4 BY END USER, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY ISOTOPE, 2025-2035 (USD Billion)
  2. 7.13.2 BY TARGETED RECEPTOR, 2025-2035 (USD Billion)
  3. 7.13.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.13.4 BY END USER, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY ISOTOPE, 2025-2035 (USD Billion)
  2. 7.14.2 BY TARGETED RECEPTOR, 2025-2035 (USD Billion)
  3. 7.14.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.14.4 BY END USER, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY ISOTOPE, 2025-2035 (USD Billion)
  2. 7.15.2 BY TARGETED RECEPTOR, 2025-2035 (USD Billion)
  3. 7.15.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.15.4 BY END USER, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY ISOTOPE, 2025-2035 (USD Billion)
  2. 7.16.2 BY TARGETED RECEPTOR, 2025-2035 (USD Billion)
  3. 7.16.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.16.4 BY END USER, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY ISOTOPE, 2025-2035 (USD Billion)
  2. 7.17.2 BY TARGETED RECEPTOR, 2025-2035 (USD Billion)
  3. 7.17.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.17.4 BY END USER, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY ISOTOPE, 2025-2035 (USD Billion)
  2. 7.18.2 BY TARGETED RECEPTOR, 2025-2035 (USD Billion)
  3. 7.18.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.18.4 BY END USER, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY ISOTOPE, 2025-2035 (USD Billion)
  2. 7.19.2 BY TARGETED RECEPTOR, 2025-2035 (USD Billion)
  3. 7.19.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.19.4 BY END USER, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY ISOTOPE, 2025-2035 (USD Billion)
  2. 7.20.2 BY TARGETED RECEPTOR, 2025-2035 (USD Billion)
  3. 7.20.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.20.4 BY END USER, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY ISOTOPE, 2025-2035 (USD Billion)
  2. 7.21.2 BY TARGETED RECEPTOR, 2025-2035 (USD Billion)
  3. 7.21.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.21.4 BY END USER, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY ISOTOPE, 2025-2035 (USD Billion)
  2. 7.22.2 BY TARGETED RECEPTOR, 2025-2035 (USD Billion)
  3. 7.22.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.22.4 BY END USER, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY ISOTOPE, 2025-2035 (USD Billion)
  2. 7.23.2 BY TARGETED RECEPTOR, 2025-2035 (USD Billion)
  3. 7.23.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.23.4 BY END USER, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY ISOTOPE, 2025-2035 (USD Billion)
  2. 7.24.2 BY TARGETED RECEPTOR, 2025-2035 (USD Billion)
  3. 7.24.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.24.4 BY END USER, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY ISOTOPE, 2025-2035 (USD Billion)
  2. 7.25.2 BY TARGETED RECEPTOR, 2025-2035 (USD Billion)
  3. 7.25.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.25.4 BY END USER, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY ISOTOPE, 2025-2035 (USD Billion)
  2. 7.26.2 BY TARGETED RECEPTOR, 2025-2035 (USD Billion)
  3. 7.26.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.26.4 BY END USER, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY ISOTOPE, 2025-2035 (USD Billion)
  2. 7.27.2 BY TARGETED RECEPTOR, 2025-2035 (USD Billion)
  3. 7.27.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.27.4 BY END USER, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY ISOTOPE, 2025-2035 (USD Billion)
  2. 7.28.2 BY TARGETED RECEPTOR, 2025-2035 (USD Billion)
  3. 7.28.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.28.4 BY END USER, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY ISOTOPE, 2025-2035 (USD Billion)
  2. 7.29.2 BY TARGETED RECEPTOR, 2025-2035 (USD Billion)
  3. 7.29.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.29.4 BY END USER, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY ISOTOPE, 2025-2035 (USD Billion)
  2. 7.30.2 BY TARGETED RECEPTOR, 2025-2035 (USD Billion)
  3. 7.30.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.30.4 BY END USER, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Isotope (USD Billion, 2025-2035)

Fluorine - 18
Gallium - 68
Lutetium - 177
Others

Healthcare By Targeted Receptor (USD Billion, 2025-2035)

Prostate-specific Membrane Antigen (PSMA)
Somatostatin Receptor (SSTR)
Epidermal Growth Factor Receptor (EGFR)
Others

Healthcare By Indication (USD Billion, 2025-2035)

Prostate Cancer
Neuroendocrine Tumors (NETs)
Breast Cancer
Others

Healthcare By End User (USD Billion, 2025-2035)

Hospitals & Clinics
Diagnostic Centers
Others

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓